Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

Ruxolitinib cream, a topical Janus kinase (JAK) 1/2 inhibitor, was initially approved by the FDA as a treatment for AD in September 2021. 1 This was based on data from the TRuE-AD (Topical ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Preliminary data from an ongoing trial of ruxolitinib cream in PN did not show a significant difference in itch from the vehicle control group, which had an increased placebo response.

Incyte (INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies – evaluating the safety ...

TRuE-PN1 Study: 44.6% of PN patients using ruxolitinib cream saw ≥4-point WI-NRS4 improvement at Week 12 vs. 20.6% with vehicle control. TRuE-PN2 Study: The primary endpoint missed statistical ...